Expansion Of Induction Of Buprenorphine Via Telemedicine Encounter

On March 1, 2023, the U.S. Drug Enforcement Administration published this notice of proposed rulemaking for expansion of induction of buprenorphine via telemedicine encounter. This rule expands the circumstances under which individual practitioners are authorized to prescribe schedule III–V narcotic drugs or combinations of such drugs that have been approved for use in continuous medical treatment (also referred to as maintenance) or withdrawal management treatment (also referred to as detoxification)—via a telemedicine encounter, including an audio-only telemedicine encounter . . .